Cargando…
Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma
Metastatic renal cell carcinoma with sarcomatoid histology (SmRCC) is associated with poor survival. No data is available from randomized trials on the efficacy of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors in SmRCC. We identified SmRCC patients fro...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320862/ https://www.ncbi.nlm.nih.gov/pubmed/25688268 http://dx.doi.org/10.1155/2015/181926 |
_version_ | 1782356201630072832 |
---|---|
author | Tantravahi, Srinivas K. Albertson, Daniel Agarwal, Archana M. Ravulapati, Sowmya Poole, Austin Patel, Shiven B. Hawatmeh, Jamil S. Straubhar, Alli M. Liu, Ting Stenehjem, David D. Agarwal, Neeraj |
author_facet | Tantravahi, Srinivas K. Albertson, Daniel Agarwal, Archana M. Ravulapati, Sowmya Poole, Austin Patel, Shiven B. Hawatmeh, Jamil S. Straubhar, Alli M. Liu, Ting Stenehjem, David D. Agarwal, Neeraj |
author_sort | Tantravahi, Srinivas K. |
collection | PubMed |
description | Metastatic renal cell carcinoma with sarcomatoid histology (SmRCC) is associated with poor survival. No data is available from randomized trials on the efficacy of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors in SmRCC. We identified SmRCC patients from a single institutional database. To identify predictive and prognostic biomarkers, immunohistochemistry (IHC) analysis was performed on the tumor samples for downstream targets of VEGF and mTOR pathways. Survival outcomes were stratified by IHC analysis, extent of sarcomatoid component, Memorial Sloan-Kettering Cancer Center (MSKCC), and Heng risk criteria. Twenty-seven patients with SmRCC were included. First line therapy included targeted therapy (n = 19), immunotherapy (n = 4), cytotoxic chemotherapy (n = 1), and no treatment (n = 3). Median OS was 8.2 months (95% CI 3.8–14.2 months). Median survival in months, based on MSKCC and Heng risk groups, was favorable 89.3 versus 84.5, intermediate 9.5 versus 12.7, and poor 3.9 versus 5.1. None of the IHC markers predicted outcomes of treatment with VEGF or mTOR inhibitors. Only tumor IMP3 expression was associated with inferior OS, although not statistically significant (IMP3 negative 14.2 versus IMP3 positive 4.9 months; HR 0.46, 95% CI 0.16–1.21; P = 0.12). The study was limited by small sample size. |
format | Online Article Text |
id | pubmed-4320862 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-43208622015-02-16 Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma Tantravahi, Srinivas K. Albertson, Daniel Agarwal, Archana M. Ravulapati, Sowmya Poole, Austin Patel, Shiven B. Hawatmeh, Jamil S. Straubhar, Alli M. Liu, Ting Stenehjem, David D. Agarwal, Neeraj J Oncol Research Article Metastatic renal cell carcinoma with sarcomatoid histology (SmRCC) is associated with poor survival. No data is available from randomized trials on the efficacy of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors in SmRCC. We identified SmRCC patients from a single institutional database. To identify predictive and prognostic biomarkers, immunohistochemistry (IHC) analysis was performed on the tumor samples for downstream targets of VEGF and mTOR pathways. Survival outcomes were stratified by IHC analysis, extent of sarcomatoid component, Memorial Sloan-Kettering Cancer Center (MSKCC), and Heng risk criteria. Twenty-seven patients with SmRCC were included. First line therapy included targeted therapy (n = 19), immunotherapy (n = 4), cytotoxic chemotherapy (n = 1), and no treatment (n = 3). Median OS was 8.2 months (95% CI 3.8–14.2 months). Median survival in months, based on MSKCC and Heng risk groups, was favorable 89.3 versus 84.5, intermediate 9.5 versus 12.7, and poor 3.9 versus 5.1. None of the IHC markers predicted outcomes of treatment with VEGF or mTOR inhibitors. Only tumor IMP3 expression was associated with inferior OS, although not statistically significant (IMP3 negative 14.2 versus IMP3 positive 4.9 months; HR 0.46, 95% CI 0.16–1.21; P = 0.12). The study was limited by small sample size. Hindawi Publishing Corporation 2015 2015-01-20 /pmc/articles/PMC4320862/ /pubmed/25688268 http://dx.doi.org/10.1155/2015/181926 Text en Copyright © 2015 Srinivas K. Tantravahi et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Tantravahi, Srinivas K. Albertson, Daniel Agarwal, Archana M. Ravulapati, Sowmya Poole, Austin Patel, Shiven B. Hawatmeh, Jamil S. Straubhar, Alli M. Liu, Ting Stenehjem, David D. Agarwal, Neeraj Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma |
title | Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma |
title_full | Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma |
title_fullStr | Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma |
title_full_unstemmed | Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma |
title_short | Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma |
title_sort | survival outcomes and tumor imp3 expression in patients with sarcomatoid metastatic renal cell carcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320862/ https://www.ncbi.nlm.nih.gov/pubmed/25688268 http://dx.doi.org/10.1155/2015/181926 |
work_keys_str_mv | AT tantravahisrinivask survivaloutcomesandtumorimp3expressioninpatientswithsarcomatoidmetastaticrenalcellcarcinoma AT albertsondaniel survivaloutcomesandtumorimp3expressioninpatientswithsarcomatoidmetastaticrenalcellcarcinoma AT agarwalarchanam survivaloutcomesandtumorimp3expressioninpatientswithsarcomatoidmetastaticrenalcellcarcinoma AT ravulapatisowmya survivaloutcomesandtumorimp3expressioninpatientswithsarcomatoidmetastaticrenalcellcarcinoma AT pooleaustin survivaloutcomesandtumorimp3expressioninpatientswithsarcomatoidmetastaticrenalcellcarcinoma AT patelshivenb survivaloutcomesandtumorimp3expressioninpatientswithsarcomatoidmetastaticrenalcellcarcinoma AT hawatmehjamils survivaloutcomesandtumorimp3expressioninpatientswithsarcomatoidmetastaticrenalcellcarcinoma AT straubharallim survivaloutcomesandtumorimp3expressioninpatientswithsarcomatoidmetastaticrenalcellcarcinoma AT liuting survivaloutcomesandtumorimp3expressioninpatientswithsarcomatoidmetastaticrenalcellcarcinoma AT stenehjemdavidd survivaloutcomesandtumorimp3expressioninpatientswithsarcomatoidmetastaticrenalcellcarcinoma AT agarwalneeraj survivaloutcomesandtumorimp3expressioninpatientswithsarcomatoidmetastaticrenalcellcarcinoma |